Incentives and Financing Mechanisms to promote R&D for HIV/AIDS, Tuberculosis, **Malaria and Neglected Tropical Diseases**

> Viviana Munoz Tellez Manager, IAKP South Centre

Disease categories

Type I: rich and poor countries

Type II: more in poor countries


Type III: only in poor countries

HIV/AIDS


TB, Malaria

Neglected tropical diseases

Adult HIV prevalence (15-49 years), 2012 By WHO region




The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, Data Source: World Health Organization Map Production: Health Statistics and




Tuberculosis

Estimated TB incidence rates, 2012




Malaria







Status of endemicity of visceral leishmaniasis, worldwide, 2012




Distribution of countries or areas at risk of dengue transmission, worldwide, 2008



Distribution of human African trypanosomiasis (T.b.gambiense), worldwide, 2012



Trend in Product development



Why are few new medical products available for neglected diseases?

Not enough investment in research and development



Why low investment in R&D?

- Private sector:
 - R&D Costs and risks
 - Investment not likely to be recouped through sales
 - Demand is high but low individual purchasing power

Why low investment in R&D?


- Public sector:
 - Policy choice: intellectual property incentive will not drive private R&D
 - Budget restriction
 - Priority setting
 - Mismatched focus on basic research, time lags

Who should pay for R&D in neglected diseases?


• Public sector

- Donors
- Private sector


General government expenditure on health as a percentage of total government expenditure (in US\$), 2011 *



How should resources be allocated?



Health R&D Ecosystem



Source: Morel 2005, WHO 2006

More financing and other incentives

what are the options?

CEWG criteria for assessment

- Public health impact
- Efficiency/ cost-effectiveness
- Technical feasibility
- Financial feasibility
- Intellectual property
- Delinking R&D cost from price
- Access
- Governance, accountability, transparency
- Capacity-building and technology transfer for developing countries

More financing and other incentives: what are the options?

"Push" by reducing cost of R&D

Pay upfront

- Pooled funds, to whom to allocate?
- Direct grants to selected stakeholder
- Fund clinical trials in developing countries

More financing and other

incentives: what are the options?

- "Push" by reducing cost of R&D
 - Indirect
 - Open approaches to innovation: Open drug discovery, openaccess publishing
 - Mandate equitable licensing for public funded projects
 - Pre-competitive R&D platforms
 - Patent pools
 - Priority review voucher
 - Transferable intellectual property rights
 - Fast track regulatory review
 - Regulatory harmonization
 - R&D tax breaks

More financing and other incentives: what are the options?

- "Pull" by paying for R&D outputs
 - Create attractive market = how big to set the incentive?

More ideas than experience

- Purchase and procurement agreements, i.e. Advanced purchasing commitments
- Milestone prizes and end prizes
- Funds to make end-payments (Health Impact Fund)

How to mobilize more funding?

- Increase country contributions
 - Taxation

Increase donor funds

Can developing countries implement or support these mechanisms?

- Global, regional or national application
- Variance of costs among mechanisms
- Financial (resources that may be allocated) and R&D capacity (to participate in R&D activities)

Why do we need a more coordinated approach to implementation of mechanisms?

- Pooled financing for cost efficiency
- Long term sustainability /viability of R&D
- Avoid duplication and competition for funds
- Requires:
- Concerted priority setting and mechanism selection
- Agree on common principles

How to coordinate?

- Global R&D observatory
- Global agreement under WHO